Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

Better-than-expected sales of some of its new products, including Skyrizi and Rinvoq, helped AbbVie handle a sharp decline in sales of former cash-cow product Humira in the last quarter of 2023.

The demand for those two treatments offset continuing falling sales of its former blockbuster medicine, Humira. AbbVie raised its long-term outlook for Skyrizi and Rinvoq revenue. AbbVie (ABBV ...

UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ahead of AbbVie’s Rinvoq and Skyrizi three months into its ...

AbbVie recently announced the availability of its drug SKYRIZI® in Canada for treating adults with ulcerative colitis, building on Health Canada's prior approval. This significant development may ...

The positive growth drivers offsetting this loss included Skyrizi (risankizumab), an IL ... The Cliffe lab in the UVA School of Medicine is seeking a Postdoctoral Research Associate to work ...

Despite a $3.5 billion impairment charge from Emraclidine's failure, AbbVie's immunology portfolio, led by Skyrizi and Rinvoq ... being studied as a once-daily medicine for use as both a ...